What Edenbridge Pharmaceuticals does

Edenbridge Pharmaceuticals, LLC is a privately held specialty pharmaceutical company founded in 2008 and headquartered in Parsippany, New Jersey. The company focuses on identifying, developing, and marketing FDA-approved generic prescription pharmaceutical products in the United States. Its portfolio is narrowly concentrated on two generic formulations: Bumetanide Tablets USP (an authorized generic of Validus Pharmaceuticals' Bumex®, available in 0.5mg, 1mg, and 2mg strengths for the treatment of edema associated with congestive heart failure, hepatic, and renal diseases) and Ivermectin Tablets USP (a generic version of Merck's Stromectol®, 3mg strength, used to treat parasitic infections including strongyloidiasis, onchocerciasis, scabies, and head lice). Both products are manufactured to USP standards with specific tablet characteristics (color, shape, engraving codes) consistent with bioequivalence requirements.

The company's go-to-market relies on an enterprise field sales motion backed by dedicated customer service teams accessible by phone, email, and fax, with revenue generated through one-time product sales to healthcare providers, pharmacies, and pharmaceutical distributors. Distribution is intermediated through the three largest U.S. pharmaceutical wholesalers — McKesson, Cardinal Health, and HD Smith — providing national channel reach. Pricing is not publicly disclosed and is negotiated directly with customers via the customer service team. The company holds licensing/authorization relationships with Validus Pharmaceuticals (for Bumex authorized generic) and Merck & Co. (for Stromectol generic).

As of October 1, 2024, Edenbridge Pharmaceuticals, LLC began doing business as Dexcel Pharma USA, signaling a corporate identity rebrand and likely integration with a broader specialty pharmaceutical portfolio under the Dexcel brand. The company operates with 11–50 employees and is privately held with no publicly disclosed revenue or detailed ownership structure. Funding history includes a 2018 capital infusion from Tailwind Capital. Leadership comprises CEO Douglas S. Boothe and founder Patrick Chu (President & Co-Founder).

Name

Edenbridge Pharmaceuticals

Legal name

Edenbridge Pharmaceuticals, LLC

Website

https://edenbridgepharma.com

Company type

Private

Founded year

2008

Operating status

Operating

Headcount range

11–50 employees

Short description

Edenbridge Pharmaceuticals is a privately held U.S. specialty pharmaceutical company that markets two FDA-approved generic prescription products — Bumetanide and Ivermectin tablets — distributed through McKesson, Cardinal Health, and HD Smith to U.S. healthcare providers and pharmacies, and now operating as Dexcel Pharma USA.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Oral Solid Dose (OSD) Generics (HLAIABAD)

Keywords

• Generic pharmaceuticals
• Prescription medications
• Authorized generics
• Loop diuretics
• Antiparasitic drugs

Headquarters

HQ city

Parsippany

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Pharmaceutical Product Sales: Revenue generated through sale of generic pharmaceutical products (Bumetanide and Ivermectin tablets) to healthcare providers, pharmacies, and distributors. Products sold as prescription pharmaceuticals with distribution through wholesale pharmaceutical channels.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels3 records

Core offering

Edenbridge Pharmaceuticals is a specialty pharmaceutical company that identifies, develops, and markets FDA-approved generic prescription pharmaceutical products. Its focused product portfolio consists of two core therapeutics: Bumetanide Tablets USP (an authorized generic of Bumex®) for the treatment of edema associated with congestive heart failure, hepatic, and renal diseases, and Ivermectin Tablets USP (a generic of Stromectol®) for parasitic infections. Products are distributed through major U.S. pharmaceutical wholesale distributors and direct customer service channels.

Product overview

Edenbridge Pharmaceuticals is a generic pharmaceutical company offering a focused portfolio of FDA-approved generic medications. The product portfolio centers on two core therapeutics: Bumetanide Tablets, USP (an authorized generic of Bumex®) available in 0.5mg, 1mg, and 2mg strengths for edema treatment, and Ivermectin Tablets, USP (a generic of Stromectol®) in 3mg strength for parasitic infections. Products are distributed through major pharmaceutical wholesalers including McKesson, Cardinal, and HD Smith. As of October 2024, the company rebranded to Dexcel Pharma USA.

Differentiator

Problem solved

Functional benefit

Products and services

• Bumetanide Tablets, USP

Quantifiable outcome

• FDA-approved generic alternatives provide bioequivalent therapeutic effects at potentially lower costs

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Five partnerships are on record, tiered minor and core.

• Validus Pharmaceuticals LLCminorOthersEdenbridge Pharmaceuticals produces an authorized generic version of Validus Pharmaceuticals' Bumex® (Bumetanide) product. This relationship allows Edenbridge to manufacture and distribute the authorized generic version.
• Merck & Co., Inc.minorOthersEdenbridge Pharmaceuticals produces a generic version of Merck's Stromectol® (Ivermectin) product. This is a standard generic pharmaceutical licensing arrangement.
• McKessoncoreChannel Partner/ Reseller/ DistributorMcKesson distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale operations. Item #3404654ABC.
• Cardinal HealthcoreChannel Partner/ Reseller/ DistributorCardinal Health distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale network.
• HD SmithcoreChannel Partner/ Reseller/ DistributorHD Smith distributes Edenbridge's Ivermectin 3mg tablets (NDC 42799-806-01) as part of its pharmaceutical wholesale operations.

Scale indicators2 records

Recent moves6 records

Expansion highlights3 records

Direct peers

• Validus Pharmaceuticals: Brand owner of Bumex® and Edenbridge's direct licensing partner for the authorized generic Bumetanide business. Comparable as a small specialty pharmaceutical company marketing prescription products through US distribution channels.
• Upsher-Smith Laboratories: Privately held US specialty/generic pharmaceutical company with a comparable small-headcount operating model focused on niche generic and specialty prescription products distributed through the Big-3 wholesalers.
• ANI Pharmaceuticals: Specialty generic pharmaceutical company that develops, manufactures, and markets niche prescription generics. Closely comparable in business model, distribution channels, and focus on limited-competition generic opportunities.
• Westminster Pharmaceuticals: Smaller specialty generic pharmaceutical company marketing niche prescription products through US wholesale distribution. Comparable in scale and product-portfolio concentration.
• Padagis: Specialty generic pharmaceutical company (formerly Perrigo's generics prescription business) focused on niche generic prescription products including topical and difficult-to-formulate generics. Similar target customer base and distribution model.

Broad incumbents

• Amneal Pharmaceuticals: Large US-based generic and specialty pharmaceutical manufacturer. A broader incumbent offering extensive generic injectable, oral solid dose, and specialty products across most therapeutic categories.
• Lupin Pharmaceuticals: Major global generic pharmaceutical manufacturer with substantial US commercial presence. Competes indirectly in the same generic therapeutic categories through broader portfolio scale.
• Endo Pharmaceuticals: Specialty and generics pharmaceutical company with a portfolio that overlaps Edenbridge's therapeutic focus areas (e.g., cardiovascular and specialty prescription products). Larger incumbent with broader commercial reach.

Emerging players

• Heritage Pharmaceuticals (Aceto-owned): Generic pharmaceutical company marketing prescription generic products in similar therapeutic categories. Comparable scale and go-to-market approach through Big-3 wholesalers.
• Glenmark Pharmaceuticals: India-headquartered global generic pharmaceutical company with growing US generic business. Emerging competitive presence in oral solid dose generics distributed through US wholesalers.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Edenbridge Pharmaceuticals